Latest News

  • INVESTMENT

    12 Jan 2026

    Lilly’s Ventyx Deal Points to a Future Beyond Injections

  • MARKET TRENDS

    8 Jan 2026

    Oral Weight Loss Pills Are Shaking Up Metabolic Care

  • PARTNERSHIPS

    6 Jan 2026

    Pfizer’s Metsera Deal Ignites a New Obesity Drug Arms Race

  • RESEARCH

    19 Dec 2025

    Liver-First Drugs Redefine the Next Phase of the MASH Race

FDA Pilot Voucher Signals Faster Reviews for Metabolic Drugs

Business discussion reflecting FDA pilot voucher accelerating metabolic drug reviews

REGULATORY

18 Dec 2025

A new FDA pilot voucher could shrink review timelines for select obesity and diabetes drugs, stirring optimism and debate across the sector

Two Victoza liraglutide injection pens displayed on a light wooden surface.

MARKET TRENDS

2 Sep 2025

First Generic GLP-1 for Weight Loss Sparks New Battle in US Market

Teva's launch of a Saxenda copy shakes up pricing power, forcing Novo and Lilly to rethink access and affordability.

White Novo Nordisk flags wave on tall poles against a cloudy sky, representing the company’s global presence.

PARTNERSHIPS

29 Aug 2025

Novo Nordisk Bets $550M on RNA's Next Act

Novo Nordisk partners with Replicate Bioscience to develop RNA-based obesity therapies, aiming to evolve beyond current GLP-1 blockbusters...

Smartphone showing glucose tracking app beside an arm-worn glucose sensor.

TECHNOLOGY

21 Aug 2025

AI Joins the Fight Against Obesity

FDA clears Dexcom and Signos tools as insurers and clinicians weigh digital alternatives to costly weight-loss drugs

Close-up of Wegovy semaglutide injection pens arranged in rows.

REGULATORY

17 Aug 2025

Conditional FDA Approval Puts Wegovy on Watch

US regulator clears Novo Nordisk drug for MASH, but continued approval to depend on long-term trial data

Hand holding smartphone with Superluminal logo against red tech-themed background.

INSIGHTS

14 Aug 2025

The Next Obesity Breakthrough Could Be Written in Code

Eli Lilly partners with Superluminal to tap Al for faster obesity drug discovery beyond injectables.

Brown pill bottles labeled Aleniglipron with white tablets on a gray surface.

INVESTMENT

7 Aug 2025

Structure Extends Runway to 2027 Ahead of Key 2025 Data

Structure raised $300M to advance its oral GLP-1 pill, with key data due in 2025 and cash runway into 2027.

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.